Clinical Trials Logo
  1. Home
  2. Psychotic Disorders
  3. NCT01688765
  4. Details
NCT01688765 Clinical Trial

Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis

Psychotic Disorders Clinical Trial

Official title:
Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01688765
Other study ID # 2012P001796
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 17, 2012
Est. completion date September 23, 2022

Study information
Verified date September 2022
Source Mclean Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate the structural, functional and chemical brain abnormalities in patients with first episode psychosis and assess the evolution of these abnormalities during the course of the disease.

Description:

The purpose of this study is to investigate the structural, functional and chemical brain abnormalities in patients with first episode psychosis and assess the evolution of these abnormalities during the course of the disease. The study design is case-control, there are no interventions.

Recruitment information / eligibility
Status Completed
Enrollment 187
Est. completion date September 23, 2022
Est. primary completion date September 23, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of first episode of a psychotic disorder - Healthy controls with no psychiatric disorder history Exclusion Criteria: - Significant neurological or medical illness history - Ages <18 or >45

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Observational

Locations
Country Name City State
United States McLean Hospital Belmont Massachusetts

Sponsors (1)
Lead Sponsor Collaborator
Mclean Hospital

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Terminated NCT03230097 - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year Phase 2
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Terminated NCT02584114 - Brain Effects of Memory Training in Early Psychosis N/A
Completed NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Terminated NCT02841956 - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement N/A
Completed NCT01981356 - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Phase 0
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Recruiting NCT02848469 - Irish Omega-3 Study Phase 2
Recruiting NCT02009969 - Serial Comparisons of Abdominal and Neurological MRI Scans N/A
Completed NCT02648321 - Motivational Intervention for Physical Activity in Psychosis N/A
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) Phase 2
Completed NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Phase 4
Completed NCT00226278 - Safety Study of ORG 34517 for Major Depression With Psychotic Features Phase 2